New drug targets Parkinson's protein in Early-Stage trial
NCT ID NCT07216066
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This study tests an experimental drug called ALN-SNCA in 46 people with early Parkinson's disease. The drug aims to lower a harmful protein (alpha-synuclein) in the fluid around the brain and spinal cord. The main goal is to check if the drug is safe and tolerable, and to see how it affects the body. This is a first-in-human trial, so it focuses on safety and dosing, not yet on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Human Drug Research
RECRUITINGLeiden, South Holland, 2333 CL, Netherlands
-
Montreal Neurological Institute and Hospital
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
Conditions
Explore the condition pages connected to this study.